Physician profile
Connie Du
NPI 1619459435
$8,480.01
in general payments reported to CMS, 2019-2025
36 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,919 · 2022: $1,888 · 2023: $1,505 · 2024: $1,919 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,672.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,921.15 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,238.82 | 2021-2025 | |
| Mannkind Corporation | $941.86 | 2021-2023 | Afrezza |
| Amgen INC. | $544.64 | 2021-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $470.57 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $458.53 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $319.49 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $284.72 | 2021-2024 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $279.44 | 2021 | |
| Esperion Therapeutics, INC. | $226.86 | 2021-2025 | Nexletol |
| Glaxosmithkline, LLC. | $226.19 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $216.24 | 2022 | |
| Sanofi-Aventis U.S. LLC | $155.41 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.53 | 2021-2024 | Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $110.10 | 2024-2025 | Rexulti, Abilify Maintena |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $106.69 | 2021-2022 | |
| Corcept Therapeutics | $84.51 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $84.32 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $70.25 | 2024-2025 | Spravato |
| Aimmune Therapeutics, INC. | $69.71 | 2024-2025 | Zenpep |
| Astellas Pharma US INC | $59.36 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $56.40 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.75 | 2024-2025 | Caplyta |
| Zealand Pharma US, INC. | $48.55 | 2022 | |
| Idorsia Pharmaceuticals US INC | $43.78 | 2023-2024 | Quviviq |
| Cequr Corporation | $38.92 | 2024-2025 | Cequr Simplicity |
| Sumitomo Pharma America, INC. | $37.48 | 2024-2025 | Gemtesa |
| Insulet Corporation | $35.54 | 2021-2023 | Omnipod |
| Inspire Medical Systems, INC. | $33.90 | 2024 | Inspire |
| Dexcom, INC. | $27.46 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $24.48 | 2024 | Vyepti |
| Tris Pharma INC | $22.07 | 2024 | Dyanavel Xr |
| Endogastric Solutions, INC | $21.03 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.35 | 2024 | Edarbi |
| Corium, LLC | $14.54 | 2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $13.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connie Du listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.